Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2 omicron variant. The booster is meant for the 12 and older age group. Pfizer’s application includes clinical data for bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies’ bivalent Omicron BA.4/BA.5-adapted vaccine.
Pfizer today also released updated data on the efficacy of its COVID-19 vaccine when used for children between the ages of six months and four years old, indicating a 70% effectiveness across existing SARS-CoV-2 variants.
Related News Articles
Headline
The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to…
Headline
Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under…
Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…
Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…